Evidence map›Paper›PMID 38081885›Full record

ArticleScientific reports2023

Clinical characteristics of Long COVID patients presenting to a dedicated academic post-COVID-19 clinic in Central Texas.

Rija Aziz, Nadia Siles, Mary Kelley, Dennis Wylie, Esther Melamed, W Michael Brode

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06821087 (Evaluating the Neuromodulatory Effect of Ketamine in Long COVID), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06821087 phase2completednot on this mapstarted 2025, after this paper: background citation

Evaluating the Neuromodulatory Effect of Ketamine in Long COVID: A Pilot Study Targeting Fatigue and Neurocognitive Symptoms

TypeinterventionalSponsorUniversity of Texas at AustinRan2025 to 2026Enrolled20ConditionsLong COVIDArmsKetamine only
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rija AzizDepartment of Internal Medicine, Dell Medical School, University of Texas at Austin, Austin, USA.
Nadia SilesDepartment of Neurology, Dell Medical School, University of Texas at Austin, Austin, USA.
Mary KelleyDepartment of Neurology, Dell Medical School, University of Texas at Austin, Austin, USA.
Dennis WylieDepartment of Neurology, Dell Medical School, University of Texas at Austin, Austin, USA.
Esther MelamedDepartment of Neurology, Dell Medical School, University of Texas at Austin, Austin, USA.
W Michael BrodeDepartment of Internal Medicine, Dell Medical School, University of Texas at Austin, Austin, USA. william.brode@austin.utexas.edu.
The University of Texas at Austin · US

Funding

Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple SclerosisK08AA027837 · NIAAA · UNIVERSITY OF TEXAS AT AUSTIN · PI MELAMED, ESTHER · 2020 to 2024
$971k
NIAAA NIH HHS K08 AA027837
6 · The paper itself

Abstract

Post-acute sequelae SARS-CoV-2 (PASC), also known as Long COVID, is a complex and widely recognized illness with estimates ranging from 5 to 30% of all COVID-19 cases. We performed a retrospective chart review of patients who presented to a dedicated Post-COVID-19 clinic between June 2021 and May 2022. The median patient age was 44.5 years, 63.5% patients were female, and patients presented at a median of 10.4 months from acute COVD-19 infection. 78% self-identified their race as white, and 21% identified as Latino ethnicity. During the acute COVID-19 infection, 50% of patients experienced moderate disease severity and 10.5% were hospitalized. The top three co-morbid conditions prior to SARS-CoV-2 infection included mental health conditions, hypertension and asthma. Patients reported a median of 18 new symptoms following COVID-19 illness, the most common were fatigue (89%), forgetfulness or "brain fog" (89%), and difficulty concentrating (77%). MoCA (Montreal Cognitive Assessment) assessment demonstrated that 46% had mild cognitive dysfunction. PHQ-9 (Patient Health Questionnaire) testing revealed 42% had moderate to severe depression, and 38% had moderate to severe anxiety on the GAD-7 (Generalized Anxiety Disorder) assessment. Symptom burden was similar across gender, age, and initial disease severity. PASC patients presenting to an academic Post-COVID-19 clinic experienced numerous multisystem symptoms and functional impairment, independent of the initial COVID-19 disease severity.

Indexed as

COVID-19Post-Acute COVID-19 SyndromeAdultDisease ProgressionFemaleHumansMaleRetrospective StudiesSARS-CoV-2Texas

Identifiers

PMID38081885
PMCPMC10713530
OpenAlexW4389549729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.